secwatch.observer — SEC 8-K summary
======================================

Issuer:     CITIUS ONCOLOGY, INC. (CTOR)
CIK:        0001851484
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001213900-25-102625
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Oncology shareholders approve doubling of stock incentive plan shares to 30M
--------------------------------------------------------------------------------

- At Oct 27 annual meeting, shareholders elected Class I directors Myron Holubiak and Joel Mayersohn for three-year terms.
- Shareholders approved amendment to 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15M to 30M.
- Ratification of Wolf & Company as independent auditor for fiscal year ending Sep 30, 2025 passed with 77.7M votes in favor.
- Plan amendment doubles share pool for equity awards; approved by board Sep 19, 2025, now effective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/0001213900-25-102625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1851484/000121390025102625/ea026265801-8k_citiusonc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-102625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer